Pharmacoeconomic review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus
Belimumab (Benlysta) inhibits the B-lymphocyte simulator, and thus inhibits B cells, which are believed to play an important role in the pathophysiology of systematic lupus erythematosus (SLE). It is indicated, in addition to standard therapy, for reducing disease activity in adult patients with act...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
2020, June 2020
|
Edition: | Final (with redactions) |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references